ClinConnect ClinConnect Logo
Search / Trial NCT06529848

Impact of Exercise Training on Ischemia With Non-Obstructive Coronary Arteries (INOCA): The ExINOCA Study

Launched by BISPEBJERG HOSPITAL · Jul 29, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

The ExINOCA Study is looking at why some people experience chest pain even when their heart arteries appear normal. This condition is known as coronary microvascular disease (CMD), which means the tiny blood vessels in the heart aren't working as well as they should. The study aims to find out if regular exercise can help improve the function of these small blood vessels and also reduce chest pain. Researchers believe that if the heart's microvascular function is reduced, it may also affect blood vessels in other parts of the body.

To participate in the study, you need to be between 18 and 262 years old and have signs of coronary microvascular dysfunction without any major blockages in your heart arteries. However, some people may not be eligible, such as those with severe heart failure or certain health conditions that would make it unsafe for them to exercise. If you join the study, you can expect to engage in a supervised exercise program and be closely monitored to see how your heart and other blood vessels respond to the training. This is an important opportunity to contribute to our understanding of CMD and explore how exercise might help improve heart health.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Coronary microvascular dysfunction, defined as myocardial bloodflow reserve (MBFR) \< 2.5 or hyperemic myocar-dial blood flow (hMBF)\<2.3 ml/g/min using \[15O\]H2O-PET
  • No obstructive coronary artery disease
  • Exclusion Criteria:
  • Females of childbearing potential (defined as a premeno-pausal female capable of becoming pregnant). The female patient must either be postmenopausal, defined as amen-orrhea for at least 1 year, or surgically sterile
  • Heart failure, defined as left ventricular ejection fraction of less than 40%
  • Uncontrolled hypertension defined as blood pressure above target 140/90 for all
  • Co-morbidity resulting in \<1 year expected survival
  • Considered by the investigator, for any reason, to be an un-suitable candidate for the study.
  • Unable or unwilling to exercise, e.g. due to arthritis or in-jury\*
  • Already are regularly physically active and/or have a maxi-mal oxygen uptake \>45 ml/kg/min

About Bispebjerg Hospital

Bispebjerg Hospital is a leading healthcare institution located in Copenhagen, Denmark, renowned for its commitment to innovative medical research and clinical excellence. As a key sponsor of clinical trials, the hospital focuses on advancing healthcare by exploring novel therapies and treatment protocols across various medical disciplines. With a multidisciplinary team of experienced researchers and clinicians, Bispebjerg Hospital aims to enhance patient outcomes through rigorous scientific inquiry and evidence-based practices, while fostering collaboration with academic institutions and industry partners to drive progress in the medical field.

Locations

Frederiksberg, , Denmark

Copenhagen, , Denmark

Patients applied

0 patients applied

Trial Officials

Eva Prescott, MD, DMSc

Principal Investigator

Department of Nutrition, Exercise and sports, University of Copenhagen

Ylva Hellsten

Principal Investigator

Department of Nutrition, Exercise and sports, University of Copenhagen

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported